Click here to read the articles and view the interactive digital edition
Bridging the Gap Between Strategy and Practice in IDN Partnerships
In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).
Pharma Pulse 6/9/25: Accelerating Site Activation and Recruitment with MCRC Partnerships; Avenzo Begins Phase I/II Trial of CDK4 Selective Inhibitor for Breast Cancer
The Variation in Dual-Eligible Beneficiary Characteristics across Medicare Advantage Plan Types
A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of Medicaid coordination and integration.
Mapping the Hidden Costs
In the second part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, details what the company’s data reveals about the relationship between pharmacy access and broader health disparities in underserved communities.
Pharma Pulse 6/6/25: GLP-1 Drugs May be Linked to Elevated Risk of Serious Eye Disease; Incyte’s Zynyz Wins FDA Approval as Single and Combo Therapy for Anal Cancer
BioNTech, BMS to Co-Design and Co-Commercialize New Antibody Candidate for Various Types of Tumors
Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’
How Geospatial Mapping Reveals the Impact of Pharmacy Closures
In the first part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, explains how geospatial mapping can help identify and address emerging pharmacy deserts across the United States.
Pharma Pulse 6/5/25: Forging a Brighter Future for Rare Disease Outcomes with Specialty Pharmacy Utilization; Rethinking Clinical Trial Efficiency Amidst Cost Pressures on Pharma
The Tariff Effect: Greater Supply Chain Prepares for Repercussions
Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.
Driving Supply Chain Resilience
In the final part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses how uncertainty can help reshape the way organizations prioritize supply chain investments.
Pharma Pulse 6/4/25: Five Critical Challenges in Investigator Site Selection and How Clinical Data Science Can Solve Them; Wegovy Use Up 50% Among US Teens
Why CX Is a Difference Maker for Pharma
Direct-to-consumer and direct-to-patient models are major contributors.
Overcoming Legacy Systems
In the fourth part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, explains how migrating to cloud-based systems can help overcome this challenge.
Pharma Pulse 6/3/25: Preparing for the Pharma C-Suite; America’s Vanishing Scientific Research Workforce is a Threat to Public Health
Amplifying Workforce Development
In the third part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, comments on the role of automation and GenAI evolving in workforce development.
Bora Expands Baltimore Facility, Adds Automated Fill-Finish Line
The installation of the new vial, syringe, and cartridge line is expected to take place throughout the coming year.
Being Digitally Optimized
In the second part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses the common misconceptions supply chain leaders might have around the term, and why the processes around optimization need to change.
How Recent Executive Orders Impact the Drug Pricing Landscape
Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.
Bridging the GenAI Adoption Gap in Supply Chain
In the first part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, describes the disparity in organizations utilizing supply-chain specific applications.
FDA Grants Interchangeability Designation to Hadlima
The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands patient access in the process.
Serialization 2.0: Why It’s Time to Upgrade, and What’s at Stake
This serialization system represents a business imperative that yields significant competitive advantages.
Mercalis and PharmaCord Officially Merge, Form Valeris
The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.
How the Rise of Personalized Medicine Impacts Life Sciences’ Logistics
As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, temperature-controlled, delivery of highly individualized treatments.
A Balancing Act
In the final part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, describes best practices for balancing long-term pipeline sustainability with short-term financial returns.
Pharma Pulse 5/23/25: The Role of AI in Solving Clinical Trial Diversity and Access Challenges; FDA Advisors Unanimously Snub Pfizer's Talzenna in Broader Prostate Cancer Population
